Close
Sherri Cervantez, MD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Sherri Cervantez, MD
Dr. Sherri Cervantez is a faculty member in the Division of Hematology and Medical Oncology at the University of Texas Health Science Center San Antonio. She earned her bachelor’s degree in neuroscience and behavioral biology from Emory University. She received her medical doctorate from Virginia Commonwealth University and completed her residency in internal medicine at West Virginia University. She completed a fellowship in Hospice and Palliative Medicine at Virginia Commonwealth University prior to completing her Hematology and Oncology fellowship at UT Health San Antonio. She joined the Mays Cancer Center, home to UT Health San Antonio MD Anderson, in 2017 as Director of Palliative Oncology. Her clinical interests include lung cancers, head and neck cancers and palliative oncology.
Gender
- Female
Languages Spoken
- English
-
Credentials
Credentials
Positions
- Assistant Professor, University of Texas Health Science Center San Antonio
- Director of Palliative Oncology, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine
- American Board of Internal Medicine, Hospice & Palliative Medicine
- American Board of Internal Medicine, Oncology
- American Board of Internal Medicine, Hematology
Education
- Medical School: Virginia Commonwealth University, Medical College of Virginia, Richmond, VA
- Residency: West Virginia University Hospital, Morgantown, WV
- Fellowship:
- Virginia Commonwealth University, Medical College, Richmond, VA
- University of Texas Health Science Center San Antonio, San Antonio, TX
- Locations & Contact
-
Research & Publications
Research & Publications
View all research & publications - Sherri Cervantez, M.D.
-
Clinical Trials
Clinical Trials
Type of Cancer
Lung
ClinicalTrials.gov Identifier
NCT02154490
Principal Investigator
Sherri Cervantez, MD
S1400, "Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step) Lung-MAP Sub-Study” (CTRC #14-0036)
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new…
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sherri Cervantez, MD
A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination with Atezolizumab Compared with Atezolizumab as Maintenance Therapy in Participants with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction